Literature DB >> 32322146

Aerosolization of COVID-19 and Contamination Risks During Respiratory Treatments.

Cassandra D Benge1, John Alan Barwise1.   

Abstract

BACKGROUND: Aerosolized medications are frequently administered across the health care continuum to acutely ill patients. During viral pandemics, the World Health Organization and the Centers for Disease Control and Prevention advise the application of airborne precautions when performing aerosol-generating medical procedures, such as aerosolized medications. OBSERVATIONS: Appropriate personal protective equipment (PPE), including fit-tested particulate respirators should be worn when administering nebulized medications to patients. These PPEs have been in short supply in the US during early phases of the COVID-19 pandemic, which is increasing the risk faced by health care workers (HCWs) who are treating patients using aerosolized medications. Despite taking appropriate precautions, HCWs are becoming infected with COVID-19. This may be related to secondary exposure related to viral longevity in fugitive emissions and viability on fomites.
CONCLUSIONS: We have expanded on non-US public health recommendations to provide guidance to frontline HCWs to enhance collaboration between clinicians, who are often siloed in their clinical practices, and ultimately to protect the federal workforce, which cannot sustain a significant loss of frontline HCWs.
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2020        PMID: 32322146      PMCID: PMC7173638     

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  12 in total

Review 1.  Aerosol Delivery Devices for Obstructive Lung Diseases.

Authors:  Roy A Pleasants; Dean R Hess
Journal:  Respir Care       Date:  2018-06       Impact factor: 2.258

Review 2.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Authors:  Darren B Taichman; Joe Ornelas; Lorinda Chung; James R Klinger; Sandra Lewis; Jess Mandel; Harold I Palevsky; Stuart Rich; Namita Sood; Erika B Rosenzweig; Terence K Trow; Rex Yung; C Gregory Elliott; David B Badesch
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

3.  A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery.

Authors:  Kaitlin McGinn; Marc Reichert
Journal:  Ann Pharmacother       Date:  2015-10-05       Impact factor: 3.154

4.  AARC Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients.

Authors:  Shawna L Strickland; Bruce K Rubin; Carl F Haas; Teresa A Volsko; Gail S Drescher; Catherine A O'Malley
Journal:  Respir Care       Date:  2015-07       Impact factor: 2.258

Review 5.  Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.

Authors:  Wouter H van Geffen; W R Douma; Dirk Jan Slebos; Huib A M Kerstjens
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

Review 6.  A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome.

Authors:  Amy L Dzierba; Erik E Abel; Mitchell S Buckley; Ishaq Lat
Journal:  Pharmacotherapy       Date:  2014-03       Impact factor: 4.705

7.  Guidelines on the management of acute respiratory distress syndrome.

Authors:  Mark J D Griffiths; Danny Francis McAuley; Gavin D Perkins; Nicholas Barrett; Bronagh Blackwood; Andrew Boyle; Nigel Chee; Bronwen Connolly; Paul Dark; Simon Finney; Aemun Salam; Jonathan Silversides; Nick Tarmey; Matt P Wise; Simon V Baudouin
Journal:  BMJ Open Respir Res       Date:  2019-05-24

8.  Index patient and SARS outbreak in Hong Kong.

Authors:  Raymond S M Wong; David S Hui
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

9.  Cluster of SARS among medical students exposed to single patient, Hong Kong.

Authors:  Tze-wai Wong; Chin-kei Lee; Wilson Tam; Joseph Tak-fai Lau; Tak-sun Yu; Siu-fai Lui; Paul K S Chan; Yuguo Li; Joseph S Bresee; Joseph J Y Sung; Umesh D Parashar
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

10.  Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS).

Authors:  W H Seto; D Tsang; R W H Yung; T Y Ching; T K Ng; M Ho; L M Ho; J S M Peiris
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

View more
  5 in total

Review 1.  Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

Authors:  Gokben Sahin; Ozlem Akbal-Dagistan; Meltem Culha; Aybige Erturk; Nur Sena Basarir; Serap Sancar; Ayca Yildiz-Pekoz
Journal:  J Pharm Sci       Date:  2022-06-09       Impact factor: 3.784

2.  The outcomes and acceptance of pressurized metered-dose inhaler bronchodilators with venturi mask modified spacer in the outpatient emergency department during the COVID-19 pandemic.

Authors:  Hock Peng Koh; Nurul Shaliza Shamsudin; Marilyn May Yeen Tan; Zulsairi Mohd Pauzi
Journal:  J Clin Pharm Ther       Date:  2021-03-25       Impact factor: 2.145

3.  The Rapid Implementation of Ad Hoc Tele-Critical Care Respiratory Therapy (eRT) Service in the Wake of the COVID-19 Surge.

Authors:  Margarete Pierce; Steven W Gudowski; Karsten J Roberts; Anthony Jackominic; Karen K Zumstein; Amanda Shuttleworth; Joshua Ho; Phillip Susser; Alomi Parikh; John M Chandler; Ann Marie Huffenberger; Michael J Scott; C William Hanson; Krzysztof Laudanski
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

Review 4.  Role of helmet ventilation during the 2019 coronavirus disease pandemic.

Authors:  Ke-Yun Chao; Jong-Shyan Wang; Wei-Lun Liu
Journal:  Sci Prog       Date:  2022 Apr-Jun       Impact factor: 2.774

5.  Respiratory Distress in Hospitalized Non-Mechanically Ventilated COVID-19 Adults: A Retrospective Multicenter Cohort Study.

Authors:  Tara Liberman; Santiago Lopez; Regina Roofeh; Stephanie Izard; Sima Parikh; Edith Burns
Journal:  Am J Hosp Palliat Care       Date:  2021-08-04       Impact factor: 2.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.